bridge biotec, thinking beyond

menu.png

Bridge Biotec's nanotechnology treatments will more safely and effectively treat inflammation in skin ailments such as burns, dermatitis and psoriasis as well as inflammation based disorders such as inflammatory bowel disease, cancer and many more.

Our research and what we do

Bridge Biotec are developing novel, safe and effective treatments for serious inflammatory diseases.

We have licenced two very important components that we plan to combine to form a range of therapies aimed at treating serious inflammatory diseases.

  • Highly potent and highly specific novel peptide (“small protein”) anti-inflammatory therapeutics
  • Safe, nanoparticle delivery polmer, that will take the peptides into human cells and switch off inflammation

By combining these two important components to form its lead compound JEL3108, a new medicine to more safely and effectively treat the life threatening and disabling inflammatory diseases such as inflammatory bowel disease (IBD), atopic dermatitis and burns.

The Pipeline

Bridge Biotec’s novel medicines are short proteins (“peptides”) that can be delivered into the human cell using a patented safe nano-polymer delivery technology. These short peptides, that will be broken down into simple and naturally occurring amino acids, are highly active and exquisitely specific inflammation blockers, so only tiny doses will be required to more safely and effectively treat serious inflammatory diseases.

Our portfolio is focused on developing these novel peptide anti-inflammatories to more safely and effectively treat serious inflammatory diseases such as inflammatory bowel diseases (IBD), atopic dermatitis (AD) and burns.

Bridge Biotec will direct the lead program and provide a backup portfolio which significantly de-risks the further development of the lead project while supporting similar future drug developments.

Inflammation is a normal physiological response to a range of harmful stimuli such as irritation, tissue damage or infection and is characterised by redness, swelling and discomfort (pain or itch). Inflammation is part of the body’s innate immune response and usually clears up. However, in some circumstances the inflammatory response does not resolve spontaneously, resulting in chronic inflammation that is the underlying cause of a number of serious inflammatory diseases. We are developing new therapies that more safely and effectively treat such diseases using potent peptides targeted to key mechanisms in inflammation.

Nano-polymer delivery into the cell

We utilize a highly effective drug delivery system based on a well-described nano-polymer with over 30 years of safe human use. This system rapidly self-assembles with our peptides and “packages” them into nanoparticles. These nanoparticles greatly enhance intracellular delivery into mammalian cells.

Use of this technology allows Bridge Biotec to develop therapies against a well-validated target in new ways. It also lets us over-come the limitations of some current therapies by improving drug solubility, cellular delivery and efficacy. Finally, the ability of our nanopolymer system to deliver our peptides in active form into cells opens up exciting new possibilities for “intracellular biologics” capable of tackling attractive approaches to disease treatment that are currently perceived to be “undruggable” by conventional small molecule treatments.

FIND OUT HOW YOU CAN INVEST IN OUR TECHNOLOGY

invest in bridge biotec research

a huge market for inflammation treatment

donate to assist our research

If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.

 donate-button.png

talk to bridge biotec about investing in our work

If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.

talk-button.png

youtube bridge biotecbridge biotec facebookbridge biotec twitterbridge biotec linkedin

Contact

Email: contact@bridgebiotec.com
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

©2018 Bridge Biotec Ltd.

The BioHub at Alderley Park
Mereside, Alderley Park
Macclesfield
SK10 4TG